JPH0534339B2 - - Google Patents
Info
- Publication number
- JPH0534339B2 JPH0534339B2 JP59203273A JP20327384A JPH0534339B2 JP H0534339 B2 JPH0534339 B2 JP H0534339B2 JP 59203273 A JP59203273 A JP 59203273A JP 20327384 A JP20327384 A JP 20327384A JP H0534339 B2 JPH0534339 B2 JP H0534339B2
- Authority
- JP
- Japan
- Prior art keywords
- compound
- cancer metastasis
- cancer
- formula
- metastasis inhibitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 201000011510 cancer Diseases 0.000 claims description 35
- 206010028980 Neoplasm Diseases 0.000 claims description 33
- 150000001875 compounds Chemical class 0.000 claims description 25
- 239000002257 antimetastatic agent Substances 0.000 claims description 14
- 238000010253 intravenous injection Methods 0.000 claims description 3
- 206010027476 Metastases Diseases 0.000 description 12
- 230000009401 metastasis Effects 0.000 description 11
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 230000001394 metastastic effect Effects 0.000 description 4
- 206010061289 metastatic neoplasm Diseases 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- SQVRNKJHWKZAKO-PFQGKNLYSA-N N-acetyl-beta-neuraminic acid Chemical class CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-PFQGKNLYSA-N 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 3
- 231100000053 low toxicity Toxicity 0.000 description 3
- 230000000704 physical effect Effects 0.000 description 3
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- RTKMFQOHBDVEBC-UHFFFAOYSA-N 3-bromo-3-buten-1-ol Chemical compound OCCC(Br)=C RTKMFQOHBDVEBC-UHFFFAOYSA-N 0.000 description 2
- 229940126062 Compound A Drugs 0.000 description 2
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 102000003838 Sialyltransferases Human genes 0.000 description 2
- 108090000141 Sialyltransferases Proteins 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 229940075610 mercuric cyanide Drugs 0.000 description 2
- NGYIMTKLQULBOO-UHFFFAOYSA-L mercury dibromide Chemical compound Br[Hg]Br NGYIMTKLQULBOO-UHFFFAOYSA-L 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 230000002194 synthesizing effect Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000000235 effect on cancer Effects 0.000 description 1
- 238000000921 elemental analysis Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000010446 mirabilite Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- RSIJVJUOQBWMIM-UHFFFAOYSA-L sodium sulfate decahydrate Chemical compound O.O.O.O.O.O.O.O.O.O.[Na+].[Na+].[O-]S([O-])(=O)=O RSIJVJUOQBWMIM-UHFFFAOYSA-L 0.000 description 1
- 239000002195 soluble material Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
Landscapes
- Saccharide Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP20327384A JPS6183125A (ja) | 1984-09-28 | 1984-09-28 | 癌転移阻害剤 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP20327384A JPS6183125A (ja) | 1984-09-28 | 1984-09-28 | 癌転移阻害剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS6183125A JPS6183125A (ja) | 1986-04-26 |
| JPH0534339B2 true JPH0534339B2 (ko) | 1993-05-21 |
Family
ID=16471314
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP20327384A Granted JPS6183125A (ja) | 1984-09-28 | 1984-09-28 | 癌転移阻害剤 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS6183125A (ko) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10590384B2 (en) | 2014-01-14 | 2020-03-17 | Luterion Co., Ltd. | Luterial and method for isolating and culturing the same |
| US10624926B2 (en) | 2014-01-14 | 2020-04-21 | Luterion Co., Ltd. | Luterial and method for isolating and culturing the same |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE94395T1 (de) * | 1986-05-09 | 1993-10-15 | Pulverer Gerhard | Verwendung von spezifischen monosacchariden zur herstellung eines arzneimittels zur verhinderung von metastasen maligner tumore. |
| DE69617415T2 (de) * | 1996-02-08 | 2002-08-01 | Biseiken Co. Ltd., Nagoya | Kanzeröse metastasenbildung unterdrückendes antikrebsmittel |
| US8940719B2 (en) | 2006-07-03 | 2015-01-27 | Academia Sinica | Lithocholic acid analogues that inhibit sialyltransferase |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS57193496A (en) * | 1981-05-22 | 1982-11-27 | Kanto Ishi Pharma Co Ltd | N-acetylneuraminic acid derivative |
-
1984
- 1984-09-28 JP JP20327384A patent/JPS6183125A/ja active Granted
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS57193496A (en) * | 1981-05-22 | 1982-11-27 | Kanto Ishi Pharma Co Ltd | N-acetylneuraminic acid derivative |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10590384B2 (en) | 2014-01-14 | 2020-03-17 | Luterion Co., Ltd. | Luterial and method for isolating and culturing the same |
| US10624926B2 (en) | 2014-01-14 | 2020-04-21 | Luterion Co., Ltd. | Luterial and method for isolating and culturing the same |
Also Published As
| Publication number | Publication date |
|---|---|
| JPS6183125A (ja) | 1986-04-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5357857B2 (ja) | 抗ガン剤及びｄｎａ複製阻害剤 | |
| HU228064B1 (en) | New antiviral nucleoside derivatives | |
| EP3546450A1 (en) | Piperidine-2,6-dione derivative and treatment for ulcerative colitis | |
| JPH0534339B2 (ko) | ||
| US4650785A (en) | Pharmaceutical composition having an excellent absorption property | |
| JPH08503699A (ja) | 全身性炎症と炎症性肝炎の治療のためのピリミジンヌクレオチド前駆体 | |
| US4239905A (en) | 1-β-D-Arabinofuranosylcytosine-5'-oleyl phosphate and salts thereof | |
| PT88568B (pt) | Processo para a preparacao de derivados de sacaridos | |
| KR880001869B1 (ko) | 2-β-D-리보푸라노실셀레나졸-4-카르복사미드화합물의 제조방법 | |
| JPS59204175A (ja) | ５―フルオロウラシル誘導体を有効成分とする血小板凝集抑制剤 | |
| WO2015027669A2 (zh) | 苯基取代化合物及其药物组合物和应用 | |
| JP3667359B2 (ja) | ５−フルオロウリジン誘導体の製造および医薬組成物 | |
| JP2528370B2 (ja) | 抗腫瘍剤 | |
| JPH0421694A (ja) | 新規なヌクレオシド―リン脂質複合体 | |
| JPH0577649B2 (ko) | ||
| JPS6144897A (ja) | ５−フルオロウラシル誘導体およびこれを含有する医薬製剤 | |
| JPH0684307B2 (ja) | 新規癌転移阻害剤 | |
| NL8220420A (nl) | Farmaceutische samenstelling, die antitumoractiviteit bezit. | |
| KR101323698B1 (ko) | Ａｚｔ의 변형된 5'-포스포네이트 - 잠재적 항바이러스제 | |
| CN109528664B (zh) | 含乌苯美司-抗肿瘤药物协同前药衍生物的冻干粉剂及其制备方法 | |
| CN114225043A (zh) | 水苏糖改性物在制备用于治疗去势抵抗性前列腺癌药物中的应用 | |
| JPH03115223A (ja) | 癌転移阻害剤 | |
| JP3406334B2 (ja) | チロシン特異的リン酸化酵素阻害剤及び制癌剤 | |
| EP3753559A1 (en) | Colitis improving agent | |
| JPH04364198A (ja) | ５’−ホスファチジル−５−フルオロウリジン誘導体 |